Xiangfan Yin

TL;DR: It is suggested that although age-related physical changes in the ECM can promote tumor cell motility, they may adversely affect the motility of some immune cells, resulting in an overall change in the immune microenvironment.

TL;DR: These data suggest that this increased response in aged patients occurs even in the absence of a more complex mutational landscape, and stress the importance of considering age as a factor for immunotherapy response.

TL;DR: It is demonstrated that phenotype switching and subsequent resistance can be guided by changes in expression of receptors involved in the noncanonical Wnt5A signaling pathway, ROR1 and ROR2, and for the first time that a single signaling pathway can effectively guide the phenotypic plasticity of tumor cells, when primed to do so by a hypoxic microenvironment.

TL;DR: This exhaustive live tissue resource includes PDX from 57 samples resistant to targeted therapy, 61 samples from responders and non-responders to immune checkpoint blockade, and 31 samples from brain metastasis, and shows examples of pre-clinical trials that highlight how the PDX collection can be used to develop and optimize precision therapies, biomarkers of response, and the targeting of rare genetic subgroups.

TL;DR: It is shown that bromodomain and extraterminal (BET) inhibitors suppress ALDH activity by abrogating BRD4-mediated ALDH1A1 expression through a super-enhancer element and its associated enhancer RNA.